Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006546 · ClinicalTrials.gov registry record · Phase 1
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
A Phase 1 study of Chronic HIV Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 8
- Study locations
NCT06006546: Active Phase 1 study of Chronic HIV Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06006546 is a Phase 1 study of Chronic HIV Infection that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06006546, a Phase 1 study of Chronic HIV Infection, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Conditions Studied
Interventions
- BIOLOGICAL 426c.Mod.Core-C4b
- OTHER Adjuvant 3M-052-AF+Alum
Study Locations (8)
Georgia
- Atlanta- Ponce - Atlanta
- The Hope Clinic of the Emory Vaccine Center CRS (Site #31440) - Decatur
Washington
- Seattle Vaccine and Prevention CRS (Site # 30331) - Seattle
- Fred Hutchinson Cancer Research Center - Seattle
Alabama
- Birmingham - Birmingham
Massachusetts
- BIDMC - Boston
New York
- Columbia P&S CRS Site#30329 - New York
Pennsylvania
- University of Pittsburg - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2026-10-27 |
| Phase | Phase 1 |
What the registry record for NCT06006546 still lists
NCT06006546 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Chronic HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which 426c.Mod.Core-C4b is the first listed.
NCT06006546 lists 8 locations in 6 states (Georgia, Washington, Alabama).
Frequently Asked Questions
What is clinical trial NCT06006546 about?
NCT06006546 is a clinical study titled "The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies". This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
What is the current status of trial NCT06006546?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2024-01-03. Estimated completion is 2026-10-27.
What conditions does trial NCT06006546 study?
This clinical trial studies the following conditions: Chronic HIV Infection.
What interventions are being tested in trial NCT06006546?
The interventions under investigation include: 426c.Mod.Core-C4b (BIOLOGICAL), Adjuvant 3M-052-AF+Alum (OTHER).
Who is sponsoring clinical trial NCT06006546?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06006546 being conducted?
This trial has 8 study locations across Alabama, Georgia, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06006546's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI